Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
Portfolio Pulse from
Cellectar Biosciences has partnered with NorthStar Medical Radioisotopes to secure a supply of non-carrier-added Actinium-225 (Ac-225) for its clinical programs. This partnership aims to support Cellectar's expanded portfolio of clinical trials.
November 14, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cellectar Biosciences has entered into a partnership with NorthStar Medical Radioisotopes to obtain a supply of Actinium-225, which is crucial for its clinical programs. This partnership is expected to enhance Cellectar's ability to expand its clinical trial portfolio.
The partnership with NorthStar provides Cellectar with a critical supply of Actinium-225, which is essential for its clinical programs. This is likely to positively impact Cellectar's stock as it supports the expansion of its clinical trials, potentially leading to new developments and advancements in its pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90